par Anais MAX | Mar 29, 2022 | Communiqués de presse
DOWNLOAD THE PRESS RELEASE (.PDF) SYNSIGHT, a biotech company specialized in RNA-targeting small molecules drugs, today announce a $1.5 million fundraising. The financing was led by an international investor. SYNSIGHT is pleased to announce today a $1.5 million...
par Anais MAX | Déc 23, 2021 | Communiqués de presse
DOWNLOAD THE PRESS RELEASE (.PDF) Institut Imagine and SYNSIGHT are joining forces to develop research projects around innovative technological services in drug discovery. Institut Imagine and SYNSIGHT are joining their efforts and resources in joint research projects...
par Anais MAX | Déc 2, 2021 | Articles
Le Hub France IA et et la European AI Startup Landscape ont sélectionné SYNSIGHT pour intégrer la nouvelle version de la cartographie européenne des startups IA ! Le volet français a été révélé le 18 novembre dernier lors de la conférence franco-allemande AIxIA. La...
par Anais MAX | Déc 2, 2021 | Communiqués de presse
READ FULL PR Online PR News – 30-November-2021 – SYNSIGHT has a unique high-content screening platform powered by deep learning to discover and develop novel drugs primarily for RNA targets. SYNSIGHT has chosen Mcule to manage compound sourcing, storage,...
par Anais MAX | Nov 29, 2021 | Communiqués de presse
DOWNLOAD THE PRESS RELEASE (.PDF) BIOCUBATE, a chinese base biotechnology company specializing in business development and incubation of bio-innovative projects, and SYNSIGHT, a french drug discovery company based on single-cell imaging and artificial intelligence...